1578 Background: Building on lessons learned from the predecessor Oncology Care Model, the Centers for Medicare (2) dose rounding and weight-based dosing to minimize waste and improve efficiency; and (3) avoiding drugs with limited clinical benefit, such as white blood cell growth factors for metastatic tumors. While not statistically significant, we found the model reduced total Medicare spending by 646 per episode (1. 1%; 90% confidence interval CI: –1, 724, 433), likely driven by reductions in Part B systemic cancer therapy payments of 645 per episode (90% CI: –1, 622, 332). This is consistent with practice reports of implementing value-based prescribing strategies. Conclusions: Early EOM implementation results show emerging evidence of systemic cancer therapy payment reductions. These findings may reflect expanded biosimilar availability and practices' strategic focus on value-based drug substitution and dosing.
Henke et al. (Wed,) studied this question.